If you purchased PE Corporation Celera Genomics Group (“Celera Genomics”) common stock in or traceable to a Secondary Public Offering conducted by PE Corporation (“PE”) (now known as Life Technologies Corporation) on or about February 29, 2000, then you could get a payment from a class action settlement.
A class action settlement has been reached in a lawsuit pending against PE Corporation (Life Technologies Corporation) and others (collectively “Defendants”) in the United States District Court for the District of Connecticut (captioned In re PE Corporation Securities Litigation, Case No. 3:00-CV-705 (CFD)) alleging that the Defendants issued an allegedly materially false and misleading secondary public offering registration statement/prospectus dated February 29, 2000, filed in connection with a SecondaryPublic Offering of 4.37 million shares of Celera common stock at $225.00 per share (the “SPO”), in violation of Section11 of the Securities Act of 1933, according to the PE Corporation Celera Genomics Group Class Action Settlement Notice.
The PE Corporation Celera Genomics class action settlement reportedly provides for, among other things, the creation of an $11,000,000 cash settlement fund for the benefit of investors who bought shares of PE Corporation Celera Genomics Group common stock in or traceable to a Secondary Public Offering conducted by PE Corporation on or about February 29, 2000 and timely submit a valid proof of claim.
For more information on the PE Corporation Celera Genomics securities class action lawsuit settlement and potential settlement benefits, call the class action settlement administrator at 1-888-264-1311 or visit the PE Corporation Celera Genomics securities class action settlement website:
www.gardencitygroup.com/cases/fullcase/1620
If You Have Thoughts On ThePE Corporation Celera GenomicsSecurities Class Action Lawsuit Settlement, Share Your Settlement Comments Below.
A very important cause. Can I suggest an article about the impact of Washington’s 2009 American Recovery and Reinvestment Act on the state of genomics? It would be interesting to hear how the stimulus package affected your research? May be of interest. http://www.americanbiotechnologist.com/blog/funding-genomics-2/
I have tried to contact the liitigation phone number 1888-264-1311 and it is impossible to get in touch with any human being.
I am very frustrated and I am panic that PE may have gone bankrupt and they are telling us the truth.
How can I to be sure that my shares are not gone down the tube.